Calamos Advisors LLC Exelixis, Inc. Transaction History
Calamos Advisors LLC
- $16.8 Billion
- Q4 2024
A detailed history of Calamos Advisors LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 16,280 shares of EXEL stock, worth $536,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,280Holding current value
$536,588% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding EXEL
# of Institutions
517Shares Held
243MCall Options Held
2.84MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$966 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$838 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$506 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$377 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.6B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...